Gene regulator profiling in live cells for drug development
Talus Bio is revolutionizing drug development for gene regulators by enabling the ability to study gene regulatory proteins (GRPs) in a living cell environment.
About Talus
Talus Bio is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators.
Talus spun out of two leading institutions in September 2020; the University of Washington and Altius Institute for Biomedical Sciences.
We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology.
_e.png)
Our Science
Talus’ objective is to provide the first functional proteomics platform, named MARMOT, for drug discovery focused on studying full-length GRPs in their natural, unmodified cellular environment.
Use of the MARMOT platform will lead to a greater understanding of the role of GRPs in various diseases, and will facilitate the development of therapeutics against these disease-causing GRPs.
Media
Matrix-Matched Calibration Curves for Assessing Analytical Figures of Merit in Quantitative Proteomics
February 10th 2021
FierceBiotech
To tackle disease-causing genes Talus Bio takes aim at proteins switch them off.
July 26th 2021
Highly Parallel Quantification and Compartment Localization of Transcription Factors and Nuclear Proteins
February 25th 2021
Will Fondrie
"I joined Talus because I believe in the company’s technology, mission, and founders."
September 6th 2021
Lindsay Pino discusses the
challenges of making quantitative measurements in the field of proteomics.
April 21st 2021
Rico rekindled his interest in biotech as he joined Talus as their Lead Machine Learning Engineer
June 8th 2021
